L3VLUP
ProSign in

GEHC · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GEHCLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GEHC
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterGEHCLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 2021none listed holders, n.a.31 holders, $34.7bn
Q1 2022none listed holders, n.a.24 holders, $35.3bn
Q2 2022none listed holders, n.a.33 holders, $42.7bn
Q3 2022none listed holders, n.a.31 holders, $43.4bn
Q4 20221 holders, $371m31 holders, $46.6bn
Q1 202313 holders, $8.0bn33 holders, $44.3bn
Q2 202321 holders, $8.7bn37 holders, $59.6bn
Q3 202314 holders, $6.6bn44 holders, $67.6bn
Q4 202313 holders, $7.3bn45 holders, $73.6bn
Q1 202417 holders, $9.7bn41 holders, $95.3bn
Q2 202417 holders, $8.0bn43 holders, $110bn
Q3 202420 holders, $10.7bn45 holders, $107bn
Q4 202418 holders, $8.8bn46 holders, $93.9bn
Q1 202518 holders, $8.4bn42 holders, $98.4bn
Q2 202522 holders, $7.2bn43 holders, $93.2bn
Q3 202514 holders, $6.3bn39 holders, $86.7bn
Q4 202513 holders, $8.1bn41 holders, $123bn
Q1 202611 holders, $6.3bn39 holders, $106bn
Q2 20269 holders, $4.9bn44 holders, $132bn
GEHC

Ge Healthcare Technologies I

Holders
17
Reported value
$9.7bn
Buyers
10
Sellers
5

Breadth +5 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
41
Reported value
$95.3bn
Buyers
15
Sellers
27

Breadth -12 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GEHC (7)

Discovery Capital Management LLC, Egerton Capital UK LLP, PDT Partners LLC, Southeastern Asset Management Inc, Steadfast Capital Management LP, Trian Fund Management LP, Winton Group Ltd

Only LLY (31)

Acadian Asset Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Coatue Management LLC, D. E. Shaw & Co., Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →